CytomX Therapeutics, Inc. (CTMX): Price and Financial Metrics

CytomX Therapeutics, Inc. (CTMX): $1.48

0.07 (+4.96%)

POWR Rating

Component Grades








Add CTMX to Watchlist
Sign Up

CTMX Price/Volume Stats

Current price $1.48 52-week high $3.02
Prev. close $1.41 52-week low $1.04
Day low $1.43 Volume 168,847
Day high $1.50 Avg. volume 922,049
50-day MA $1.27 Dividend yield N/A
200-day MA $1.58 Market Cap 99.14M

CTMX Stock Price Chart Interactive Chart >


  • Growth is the dimension where CTMX ranks best; there it ranks ahead of 92.63% of US stocks.
  • CTMX's strongest trending metric is Stability; it's been moving up over the last 177 days.
  • CTMX ranks lowest in Momentum; there it ranks in the 4th percentile.

CTMX Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for CTMX is -1.47 -- better than just 5.01% of US stocks.
  • CTMX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 4.54% of US stocks.
  • With a year-over-year growth in debt of -29.61%, CYTOMX THERAPEUTICS INC's debt growth rate surpasses only 10.99% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to CYTOMX THERAPEUTICS INC, a group of peers worth examining would be CRDF, DBVT, HYLN, MRUS, and VYGR.
  • CTMX's SEC filings can be seen here. And to visit CYTOMX THERAPEUTICS INC's official web site, go to

CTMX Valuation Summary

  • CTMX's EV/EBIT ratio is -2.9; this is 122.83% lower than that of the median Healthcare stock.
  • CTMX's price/sales ratio has moved down 60.1 over the prior 99 months.

Below are key valuation metrics over time for CTMX.

Stock Date P/S P/B P/E EV/EBIT
CTMX 2023-11-20 1.2 -1.8 -3.2 -2.9
CTMX 2023-11-17 1.2 -1.7 -3.0 -2.7
CTMX 2023-11-16 1.1 -1.7 -2.9 -2.6
CTMX 2023-11-15 1.1 -1.7 -2.9 -2.6
CTMX 2023-11-14 1.1 -1.7 -2.9 -2.6
CTMX 2023-11-13 1.1 -1.6 -2.8 -2.5

CTMX Growth Metrics

    The 3 year cash and equivalents growth rate now stands at -14.07%.
  • Its 3 year revenue growth rate is now at -5.43%.
  • The 3 year net cashflow from operations growth rate now stands at -30.48%.
CTMX's revenue has moved up $5,523,000 over the prior 15 months.

The table below shows CTMX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 71.943 -140.586 -97.593
2022-06-30 72.615 -136.442 -96.881
2022-03-31 70.738 -130.404 -91.94
2021-12-31 69.573 -119.031 -83.609
2021-09-30 66.219 -105.266 -72.082
2021-06-30 66.42 -100.244 -64.208

CTMX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CTMX has a Quality Grade of D, ranking ahead of 22.16% of graded US stocks.
  • CTMX's asset turnover comes in at 0.169 -- ranking 210th of 682 Pharmaceutical Products stocks.
  • JNJ, LEXX, and ORGS are the stocks whose asset turnover ratios are most correlated with CTMX.

The table below shows CTMX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.169 1 -0.872
2021-03-31 0.170 1 -0.944
2020-12-31 0.255 1 -0.424
2020-09-30 0.237 1 -0.610
2020-06-30 0.219 1 -0.636
2020-03-31 0.200 1 -0.554

CTMX Price Target

For more insight on analysts targets of CTMX, see our CTMX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $13.00 Average Broker Recommendation 1.5 (Moderate Buy)

CytomX Therapeutics, Inc. (CTMX) Company Bio

CytomX Therapeutics develops a novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology. The company was founded in 2008 and is based in San Francisco, California.

CTMX Latest News Stream

Event/Time News Detail
Loading, please wait...

CTMX Latest Social Stream

Loading social stream, please wait...

View Full CTMX Social Stream

Latest CTMX News From Around the Web

Below are the latest news stories about CYTOMX THERAPEUTICS INC that investors may wish to consider to help them evaluate CTMX as an investment opportunity.

AstraZeneca (AZN) to Discontinue Two Studies on Lokelma

Owing to increased enrollment timelines and low event rates, AstraZeneca (AZN) plans to stop the STABILIZE-CKD and DIALIZE-Outcomes phase III evidence studies for the hyperkalemia drug Lokelma.

Yahoo | December 1, 2023

Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why

Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease.

Yahoo | December 1, 2023

AbbVie (ABBV) Posts Encouraging Data From Lung Cancer Study

Data from a mid-stage study on AbbVie's (ABBV) experimental ADC drug demonstrates compelling clinical benefits across key endpoints in certain lung cancer patients.

Yahoo | November 30, 2023

Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND

Adaptimmune (ADAP) shares rise as GSK transfers IND for letetresgene autoluecel (lete-cel), which is being developed for treating synovial sarcoma and myxoid/round cell liposarcoma.

Yahoo | November 30, 2023

Emergent (EBS) Gets $75M BARDA Contract for Anthrax Vaccine

The BARDA is exercising an option to procure additional doses of Emergent BioSolutions' (EBS) recently approved anthrax vaccine. Deliveries will likely be completed by the end of first-quarter 2024.

Yahoo | November 29, 2023

Read More 'CTMX' Stories Here

CTMX Price Returns

1-mo 16.54%
3-mo 7.25%
6-mo -11.90%
1-year -9.76%
3-year -80.00%
5-year -89.50%
YTD -7.50%
2022 -63.05%
2021 -33.89%
2020 -21.18%
2019 -44.97%
2018 -28.47%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!